Compare Fabrinet (FN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fabrinet vs State Street SPDR S&P Biotech ETF — how do they compare? Fabrinet trades at $572.26 (market cap $18.84B), while State Street SPDR S&P Biotech ETF trades at $159.5. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Fabrinet nearer its low. Which is the better fit depends on your goals.
| FN | XBI | |
|---|---|---|
Market Cap | $18.84B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $746.47 | $164.28 |
52-Week Low | $277.04 | $86.92 |
Enterprise Value | $17.90B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fabrinet (FN) trades at $583.95, up 10.79% in 24 hours, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $3.81. Revenue grew to $3.42 billion in 2025, with a net income margin of 9.94%, while the company maintains a debt-free balance sheet and strategic positioning in AI optical supply chains.
Outlook is positive due to robust AI-driven demand and expansion plans, though risks include premium valuation (P/E 45.18) and supply chain constraints. Analysts are bullish with 75% buy ratings and a $661.75 price target (MarketBeat, 2026-07-07), but technical indicators suggest near-term resistance near $532.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
